Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed MET amplification after prior EGFR-TKI therapy in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›
Nivolumab in combination with ipilimumab delivers durable, long-term survival benefit versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression with 4 years of follow-up. Read More ›
First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up. Read More ›
Comprehensive biomarker testing and clinical trial participation rates were significantly lower for black patients in the United States compared with white patients with advanced non–small-cell lung cancer (NSCLC). Read More ›
Findings of a global ancestry analysis confirm that African ancestry is associated with worse survival outcomes among patients with lung adenocarcinoma. Read More ›
Deep and durable responses with a manageable toxicity profile were achieved with capmatinib treatment in patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy. Read More ›
In this study of the impact of tucatinib in patients with HER2-positive metastatic breast cancer with stable and active brain metastases, health-related quality of life was maintained, while significant and clinically meaningful improvement in overall survival was observed.
Read More ›
Patients with HER2-positive metastatic breast cancer treated with ≥2 lines of HER2-directed therapy had better outcomes in the neratinib plus capecitabine arm compared with the lapatinib plus capecitabine arm irrespective of the baseline status of CNS metastases.
Read More ›
To evaluate the use of tucatinib with T-DM1 for unresectable locally advanced or metastatic HER2-positive breast cancer, enrollment for the HER2CLIMB-02 trial is ongoing in the United States and planned internationally.
Read More ›
In this final overall survival analysis of ExteNET, there were fewer deaths with neratinib despite not reaching statistical significance and greater overall survival with neratinib in subgroups.
Read More ›